GlassScriptPhysician profile
Amy C Brownlee
NPI 1104993401
$22,874.28
in general payments reported to CMS, 2019-2025
35 companies · $4,408 in 2025
The $4,408 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,809 · 2022: $2,405 · 2023: $5,820 · 2024: $5,432 · 2025: $4,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,300 · Consulting Fee: $1,400 · Education: $286 · Travel and Lodging: $41.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,632.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,300.00 |
| Consulting Fee | $1,400.00 |
| Education | $286.38 |
| Travel and Lodging | $41.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,562.11 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $3,897.18 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Genzyme Corporation | $1,406.25 | 2021-2025 | |
| Incyte Corporation | $1,202.42 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $952.87 | 2022-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $917.61 | 2021-2025 | |
| Janssen Biotech, INC. | $870.43 | 2021-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $865.09 | 2021-2025 | |
| Lilly USA, LLC | $799.06 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $796.66 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $790.08 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $727.70 | 2022-2024 | Vtama |
| Journey Medical Corporation | $717.79 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $601.74 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $496.79 | 2021-2025 | Aklief |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $492.03 | 2021-2022 | |
| Leo Pharma INC. | $406.36 | 2021-2025 | Adbry |
| Ucb, INC. | $367.90 | 2023-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $299.78 | 2021-2025 | |
| Smith+Nephew, INC. | $260.56 | 2021-2024 | Grafix Pl |
| Almirall LLC | $214.61 | 2021-2023 | Seysara |
| Botanix Sb INC | $199.24 | 2025 | Sofdra |
| Organon LLC | $193.81 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $169.85 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $139.15 | 2021 | |
| Epi Health, LLC | $123.12 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.37 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Vyne Pharmaceuticals INC. | $70.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $53.50 | 2025 | Acthar |
| Merz North America, INC. | $41.54 | 2021-2024 | |
| Medimetriks Pharmaceuticals, INC. | $36.78 | 2022 | |
| Lnhc, INC | $28.79 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $23.21 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2023 | Spevigo |
| Mission Pharmacal Company | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Brownlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.